Kolexia
Gomez-Roca Carlos Oncologie médicale
Gomez-Roca Carlos
Oncologie médicale
Oncopole Toulouse
Toulouse, France
262 Activités
511 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Mélanome Tumeurs du poumon Carcinome épidermoïde Carcinome pulmonaire non à petites cellules Tumeurs colorectales Récidive tumorale locale Carcinome pulmonaire à petites cellules Sarcomes

Collaborateurs

Voir plus
Delord Jean-Pierre
Delord Jean-Pierre
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Cassier Philippe
Cassier Philippe
Centre Léon-Bérard, Lyon, France
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Le Tourneau Christophe
Le Tourneau Christophe
Clcc Institut Curie, Paris, France

Industries

Voir plus
M3 Global Research Ltd
129 collaboration(s)
Dernière en 2023
All Global
83 collaboration(s)
Dernière en 2021
KANTAR PROFILES HEALTH
30 collaboration(s)
Dernière en 2023
A+A
24 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC): A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Essai Clinique (Roche)   01 mars 2024
AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.
Essai Clinique (Unicancer)   26 février 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Nature communications   24 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE): A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Essai Clinique (PMV Pharmaceuticals, Inc)   07 février 2024
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors: A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Essai Clinique (BMS)   06 février 2024
30P OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies
Abstract Book of the ESMO Targeted Anticancer Therapies Congress (TAT) 26 - 28 February 2024   01 février 2024
SLEEP_CTC: Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
Essai Clinique (Institut Universitaire du Cancer Toulouse Oncopole)   31 janvier 2024
Study of DF1001 in Patients With Advanced Solid Tumors: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Essai Clinique (Dragonfly Therapeutics)   25 janvier 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Science translational medicine   24 janvier 2024